Address:
,China
Main Products:
Cialis (Tadalafil),Testosterone acetate,Oxymetholone (Anadrol) ,Letrazole(Femara),Sustanon 250,Trenbolone Acetate
Letrozole
Basic information:
Product Name: Letrozole
Synonyms: 4,4'-(1H-1,2,4-TRIAZOL-1-YLMETHYLENE) BIS-BENZONITRILE;FEMARA;CGS-20267;LETROZOL;LETROZOLE;LetrozoleUsp28;Letrozole99%;CGS-20267, Femara
CAS: 112809-51-5
MF: C17H11N5
MW: 285.3
Product Categories: Anti-Cancer;Pharmaceutical material and intermeidates;Active Pharmaceutical Ingredients;Letrozole;Antineoplastic;All Inhibitors;anti-neoplastic;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;API's;APIs;Antibiotics;Aromatics;Heterocycles;ELOXATIN;Anti-cancer&immunity
Mol File: 112809-51-5.mol
Chemical Properties:
MP 181-183°C
storage temp. -20°C Freezer
CAS DataBase Reference 112809-51-5(CAS DataBase Reference)
Safety Information:
Hazard Codes Xi
Risk Statements 36/37/38
Safety Statements 26-36
Appearance white to light yellow crystal
Hazardous Substances Data 112809-51-5(Hazardous Substances Data)
Pharmacological Function:
Letrozole is a new generation of selective aromatase inhibitors. It is a synthetic benzyl triazole derivative, can inhibit aromatase and decrease estrogen levels, further eliminates the stimulation of estrogen on tumor growth. The activity of letrozole in the body is 150-250 times more than that of the first generation of aromatase inhibitors - aminoglutethimide. Due to its high selectivity, and shall not affect the sugar cortical hormone, mineralocorticoid and thyroid functions, large dosage is of no inhibition for adrenal corticosteroid secretions, therefore, it has a higher therapeutic index. Preclinical studies have shown that Letrozole is of no potential toxicity to each system and target organ in the body, no mutagenic and carcinogenic effect, little side reaction, well tolerated, and compared with other aromatase inhibitors and anti-estrogen drugs, it has a stronger antitumor effect. Applicable to the treatment of advanced breast cancer in postmenopausal patients who anti-estrogen ineffective, and early breast cancer.
In December 2005, the British drug and health care products regulatory approved letrozole (furlong) produced by Swiss Novartis used to treat breast cancer patients, and allowed it to treat early invasive breast cancer patients after the surgery caused by positive postmenopausal hormone. This is the second aromatase inhibitors approved by UK after Astrazeneca's Arimidex June in 2005. Two drugs in clinical trials have shown that compared with the current standard Tamoxifen treatment, it can better prevent the risk of breast cancer recurrence.
Usage And Synthesis:
1.Pyrrole type aromatization enzyme inhibitors. Used in the treatment of breast cancer.
2.A nonsteroidal aromatase inhibitor structurally related to Fadrozole. Antineoplastic
Adverse Reactions and Side Effects:
Randomized trials show that orally take 2.5 mg of letrozole every day, adverse reactions incidence may be related to the drug is 33%, and is significantly less than that of the AG group which is 46%. Most adverse reactions of letrozole are mild or moderate, mainly include nausea (2% ~ 9%), headache (0% ~ 7%), bone pain (4% ~ 10%), hot flashes (0% ~ 9%) and weight gain (2% ~ 8%), and other rare reactions like constipation, diarrhea, itching, rash, joint pain, chest pain, abdominal pain, fatigue, insomnia, dizziness, edema, hypertension, arrhythmia, thrombosis, difficulty breathing, vaginal bleeding, etc.
Safe and discreet package
1).All products will have been strictly Quality Checked in house before packing. 2).All products will be well packed before shipping. 3)Parcel can be sent out in 24 hours after payment. Tracking number available 4)Secure and discreet shipment. Various transportation methods for your choice. 5)Customs pass rate ≥99% 6) We have our own agent/remailer/distributor who can help us ship our products very fast and safe, and we have stock in there for transferring.